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Introduction
• Epistaxis is one of the most common ear,
nose, and throat emergencies in an
emergency department or primary care
setting
• Oral anticoagulant medications (e.g.,
warfarin, apixaban, or rivaroxaban) and
antiplatelet medication (e.g., aspirin and
clopidogrel) are known to increase the risk
of bleeding
• There is still debate on the degree that
anticoagulation and antiplatelet therapy
has on patient length of stay (LOS)

Problem Statement
The primary goal of this project was to establish
if the type of medication (e.g., anticoagulants,
antiplatelets, none, or both) epistaxis patients
are taking on admission influences the LOS.

Methods
• A retrospective cohort study on 119 patients
admitted for epistaxis between January 2018
and March 2020
• Patients were divided into 4 groups
– No medications (NM)
– Anticoagulant only (AC)
– Antiplatelet only (AP)
– Anticoagulant and antiplatelet therapy
(AC+AP)
• Groupings were determined by the type of
medication patients were taking at their home.

Table 1. Descriptive statistics of epistaxis
cohort.

Results

Discussion
• The AP group was found to have
the longest LOS among all groups,
followed by the AC group and the
AC+AP group
– Antiplatelet medications are
not being readily reversible
• Patients with a supratherapeutic
INR had a longer LOS than patients
with an INR in an acceptable range
• Patients with supratherapeutic
INRs had their epistaxis resolved
more quickly than the NM group.
– may indicate the NM group
was more likely to experience
true posterior epistaxis

• Descriptive characteristics of
each group (Table 1)
• N = 119 patients in total
–
–
–
–

NM group 28 (23.5%) patients
AC group 47 (39.5%) patients
AP group 16 (13.4%) patients
AC+AP group 28 (23.5%) patients
(Table 2)

• The AP group had the longest
LOS and the NM group had the
shortest (Table 3)
• Patients with supratherapeutic
INR had longer LOS than those
with INR in acceptable range
(Table 4)
• Difference in LOS between the
NM and AP groups is
significant (Table 5)
• No difference in LOS between
DOACs vs. Warfarin groups

• Goljo et al. found that the mean
hospitalization cost of epistaxis was
$6,925 and the LOS was 3.24
•
•
•
•

– LVHN is in-line with that study’s LOS
findings
AP group had the longest LOS, but
secondary intervention did not positively
correlate
The antiplatelet group had the longest LOS,
due to difficulty reversing medication effects
No difference in LOS for patients taking
DOACs vs. Warfarin
Supratherapeutic INR had the greatest
impact on a patient’s LOS in the AC or
AC+AP groups
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